Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Human brain microvascular endothelial cells forming the blood-brain barrier (BBB) release soluble vascular cell adhesion molecule-1 (sVCAM-1) under inflammatory conditions. Furthermore, sVCAM-1 serum levels in untreated patients with multiple sclerosis (MS) correlate with a breakdown of the BBB as measured by gadolinium-enhanced MRI. To date, it is unknown whether sVCAM-1 itself modulates BBB permeability. Here, we provide evidence that human brain endothelium expresses integrin α-4/β-1, the molecular binding partner of sVCAM-1, and that sVCAM-1 directly impairs BBB function by inducing intracellular signalling events through integrin α-4. Primary human brain microvascular endothelial cells showed low to moderate integrin α-4 and strong β-1 but no definite β-7 expression in vitro and in situ. Increased brain endothelial integrin α-4 expression was observed in active MS lesions in situ and after angiogenic stimulation in vitro. Exposure of cultured primary brain endothelial cells to recombinant sVCAM-1 significantly increased their permeability to the soluble tracer dextran, which was paralleled by formation of actin stress fibres and reduced staining of tight junction-associated molecules. Soluble VCAM-1 was also found to activate Rho GTPase and p38 MAP kinase. Chemical inhibition of these signalling pathways partially prevented sVCAM-1-induced changes of tight junction arrangement. Importantly, natalizumab, a neutralising recombinant monoclonal antibody against integrin α-4 approved for the treatment of patients with relapsing-remitting MS, partially antagonised the barrier-disturbing effect of sVCAM-1. In summary, we newly characterised sVCAM-1 as a compromising factor of brain endothelial barrier function that may be partially blocked by the MS therapeutic natalizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“The latter are highly dynamic trans-membrane protein complexes, tightly sealing the interendothelial clefts [46].”
BackgroundAstrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease
Argaw, A. T., Asp, L., Zhang, J., Navrazhina, K., Pham, T., Mariani, J. N., Mahase, S., Dutta, D. J., Seto, J., Kramer, E. G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60842 · Cited by 733 · cited 1×
“VEGF is strongly expressed in inflammatory-active MS lesions [35, 40], its serum levels were found to be increased during relapses [44], and astrocyte-derived VEGF mediated a disruption of the BBB in animal models of the disease [3, 4].”
BackgroundVEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown
Argaw, A. T., Gurfein, B. T., Zhang, Y., Zameer, A., & John, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808698106 · Cited by 666
Massia, S. P., & Hubbell, J. A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49672-5 · Cited by 287
Integrin modulation and signaling in leukocyte adhesion and migration
Rose, D. M., Alon, R., & Ginsberg, M. H. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00536.x · Cited by 243
HAWKINS, C. P., MUNRO, P. M. G., MACKENZIE, F., KESSELRING, J., TOFTS, P. S., BOULAY, E. P. G. H. D., LANDON, D. N., & McDONALD, W. I. (1990) · Brain · doi:10.1093/brain/113.2.365 · Cited by 219
Kallmann, B. A. (2000) · Brain · doi:10.1093/brain/123.4.687 · Cited by 106
Kooij, G., Mizee, M. R., van Horssen, J., Reijerkerk, A., Witte, M. E., Drexhage, J. A. R., van der Pol, S. M. A., van het Hof, B., Scheffer, G., Scheper, R., et al. (2011) · Brain · doi:10.1093/brain/awq330 · Cited by 90
Self-citationDore-Duffy, P., Washington, R., & Dragovic, L. (1993) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-2920-0_38 · Cited by 52 · cited 3×
“So far, it is unknown whether undiseased human brain endothelial cells or those in MS CNS lesions express the established binding partners of sVCAM-1, i.e. integrin α-4 heterodimers.”
BackgroundInterferon-β1bin multiple sclerosis
Buttmann, M., & Rieckmann, P. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.3.227 · Cited by 43
Self-citation
Cited by
Factors controlling permeability of the blood–brain barrier
Almutairi, M. M. A., Gong, C., Xu, Y. G., Chang, Y., & Shi, H. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2050-8 · Cited by 306
Cong, X., & Kong, W. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109485 · Cited by 302
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
A peripheral signature of Alzheimer’s disease featuring microbiota-gut-brain axis markers
Marizzoni, M., Mirabelli, P., Mombelli, E., Coppola, L., Festari, C., Lopizzo, N., Luongo, D., Mazzelli, M., Naviglio, D., Blouin, J.-L., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01218-5 · Cited by 121
“Microbiota‐gut‐brain axis mediators A series of markers were selected in order to investigate several possible immune and endothelial mediators of the MGBA: the gut bacteria product LPS; soluble CAMs involved in AD and indicative of endothelial damage (sVCAM-1 and sPECAM-1 [25, 26]), vascular damage (sP- and sL-Select…”
BackgroundWang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Metadata
- Authors
- Haarmann, A., Nowak, E., Deiß, A., van der Pol, S., Monoranu, C.-M., Kooij, G., Müller, N., van der Valk, P., Stoll, G., de Vries, H. E., Berberich-Siebelt, F., & Buttmann, M.
- Venue
- Acta Neuropathologica
- Published
- 2015-03-27
- Volume
- 129
- Issue
- 5
- Pages
- 639-652
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2000055713
- Cited by
- 90
- References
- 10
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.